跳至主要内容
临床试验/NCT02389179
NCT02389179Unknown4 期

Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis

Sharifah Faradila bt Wan Muhamad Hatta1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
150
试验地点
1
主要终点
Measuring optimal Vitamin D dose required to maintain vitamin D sufficiency (Serum 25(OH)D >30ng/ml in Malay and Indian PMO women.

研究概览

简要总结

Much research on vitamin D status has focused on seasonal variations in serum 25(OH)D levels in populations living at high altitudes and those of light-skinned Caucasian extraction, with little work done in multi ethnic populations living closer to the equator with regards to Vitamin d supplementation, prevalence, predictors and associations of hypovitaminosis D - the assumption, perhaps being vitamin D deficiency is unlikely in locations of plentiful sunshine. There is a dearth of studies on Vitamin D status in a group of subjects at especially high risk of falls/fractures i.e. post-menopausal women with osteoporosis living in South-East Asia. It is possible that differences in geography and ethnicity/culture amongst women with post menopausal osteoporosis (PMO) in Malaysia may necessitate supplemental Vitamin D doses that differ from those prescribed to North American Caucasians.

There is no unified consensus on the dose of Vitamin D supplementation. Neither is there agreement on definitions of sufficiency with some researchers targeting levels of serum 25(OH)D of >20ng/ml and others aiming for levels above 30ng/ml. The Institute of Medicine (IOM) 2010 guidelines, aiming for a lower serum 25(OH)D target of 20ng/ml, advocates maintenance doses of 600 IU/day in Postmenopausal women aged 51-70 and 800 IU/day for those aged >70 years. On contrary, the Endocrine Society 2011 guidelines state that maintenance doses up to 1500-2000 IU/day may be required to attain a higher optimal target of >30ng/ml. On addition, the 2014 National Osteoporosis Foundation Guidelines recommended that the Vitamin D level should be brought up to approximately 30ng/ml, and to maintain at this level taking into account those with limited sun exposure, obese and dark skin individuals, the daily requirement ranges from 800-2000 IU/day.

The investigators therefore designed a prospective randomized controlled trial comparing efficacy and safety of a low (900 IU/day) and high (1800IU/day and 3300IU/day) maintenance dose of Cholecalciferol (Vitamin D3) amongst community dwelling Indian and Malay with PMO living in Kuala Lumpur, Malaysia.

Hypothesis of the study is despite abundant exposure to sunlight, which is the main Vitamin D supplier, those who dress conservatively and individuals with darker skin may require a higher dose of Vitamin D to maintain sufficiency (>30ng/ml).

详细描述

This randomized controlled trial will evaluate the appropriate dose of Vitamin D required to maintain Vitamin D sufficiency amongst Indian and Malay PMO women. The study will last for six months. 150 PMO women of Indian and Malay ethnicity will be randomly allocated into 3 different dosing regimens i.e. (a) 25 000 IU/monthly (≈900 IU/day), (b) 50 000 IU/monthly (≈1800 IU/day) and (c) 50 000 IU/fortnightly (≈3300 IU/day). Each group will be containing an equal amount of Indian and Malay Individuals. Subjects will be recruited from the osteoporosis clinic at UMMC.

Inclusion Criteria

  1. Post menopausal Osteoporosis women receiving treatment from the Osteoporosis Clinic, University of Malaya Medical Centre, Kuala Lumpur.
  2. Resident in Malaysia, of South Indian descent or Muslim Malay wearing headscarf
  3. Baseline serum 25(OH)D levels > 20 ng/ml or 50 nmol/L

Exclusion Criteria

  1. Secondary osteoporosis e.g. glucocorticoid induced osteoporosis
  2. Metabolic bone disease e.g. hypercalcaemia, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, Paget's disease
  3. Medications that interfere with bone / vitamin D metabolism e.g. hormone replacement therapy (HRT), Recombinant human parathyroid hormone i.e. Teriparatide, glucocorticoids, rifampicin and anticonvulsants
  4. Calculated Creatinine Clearance of < 60 mls/min
  5. Liver disease and Malabsorptive Diseases e.g. celiac disease, radiation, enteritis, active inflammatory bowel disease
  6. Malignancy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post menopausal osteoporosis woman receiving treatment from the Osteoporosis Clinic, University of Malaya Medical Centre, Kuala Lumpur.
  • Resident in Malaysia, of South Indian descent or Muslim Malay wearing headscarf
  • Baseline serum 25(OH)D levels > 20 ng/ml

排除标准

  • Secondary osteoporosis e.g. glucocorticoid induced osteoporosis
  • Metabolic bone disease e.g. hypercalcaemia, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, Paget's disease
  • Medications that interfere with bone / vitamin D metabolism e.g. recombinant human parathyroid hormone i.e. Teriparatide, hormone replacement therapy (HRT), glucocorticoids, rifampicin and anticonvulsants
  • Calculated Creatinine Clearance of < 60 mls/min
  • Liver disease and Malabsorptive Diseases e.g. celiac disease, radiation, enteritis, active inflammatory bowel disease

研究组 & 干预措施

25 000 IU monthly

Active Comparator

The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.

干预措施: Vitamin D3 (Drug)

50 000 IU monthly

Active Comparator

The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.

干预措施: Vitamin D3 (Drug)

50 000 IU bi-weekly

Active Comparator

The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.

干预措施: Vitamin D3 (Drug)

结局指标

主要结局

Measuring optimal Vitamin D dose required to maintain vitamin D sufficiency (Serum 25(OH)D >30ng/ml in Malay and Indian PMO women.

时间窗: 6 months

This Randomised Control Trial will evaluate the appropriate dose of Vitamin D required to maintain sufficiency amongst Post Menopausal Malay and Indian descent Osteoporosis women.

次要结局

未报告次要终点

研究者

发起方
Sharifah Faradila bt Wan Muhamad Hatta
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Sharifah Faradila bt Wan Muhamad Hatta

Doctor

University of Malaya

研究点 (1)

Loading locations...

相似试验